drugset / Trial / NCT02041247

Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection

NCT02041247 ↗

Phase 2 Unknown 90 enrolled InnaVirVax
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the protective effect of VAC-3S in controlled HIV patients receiving standard of care antiretroviral treatment.

Timeline

Start
2014-01
Primary completion
2015-09
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator VAC-3S Vaccine 16 ug Intramuscular
Comparator VAC-3S Vaccine 32 ug Intramuscular
Comparator VAC-3S Vaccine 64 ug Intramuscular